A method of treating prostate cancer

 

The invention relates to medicine, more specifically to Oncology, and can be used in the treatment of patients with malignant prostate tumors with a significant prevalence of the process. The method includes the operation of enucleation of the testicular parenchyma and regional chemotherapy, which after enucleation secrete seminal cord, under his shell 1.5-2 cm catheter, fix it to the shell, injected into the catheter 400 mg of cyclophosphamide. Perform the same actions on the opposite side. Surgical wound is sutured in layers, the catheter is fixed to the skin. On the seventh day after the operation in each catheter re-administered 400 mg of cyclophosphamide, after which the catheters are removed. The method allows to introduce into the body a high amount of chemotherapy while reducing its toxic effects, prevents the development of new and reduces the available tumor metastases. 2 Il.

The invention relates to medicine, more specifically to Oncology, and can be used in the treatment of patients with malignant tumors of the prostate gland with a significant prevalence of the process as one of the components of therapeutic effects.

Known spacechina, first, carry out drug "castration". Inhibition of testicular function, is closely interrelated with the activities in the body of the prostate gland, is achieved by intramuscular injection of large doses of estrogen (sinistral, diethylstilbestrol or honvana, lifestylea, progynova), daily for 1.5-2 months.

With effect from the first course prescribed a small dose of any estrogen throughout life (Clinical oncourology. Under the editorship of B. Moranbah. - M.: Medicine, 1975).

Proposed and implemented a method of hormone therapy and castration leads to the achievement of the latter. However, the side effects of the hormone estrogen - cardiotoxicity, nausea, vomiting, loss of appetite, painful swelling of the breast, swelling, a very pronounced.

Most patients swell of breast cancer, increased pigmentation of the breast, okolososkovi circles, the skin of the perineum along the middle line. Breast and nipples become sharply painful, pigmentation is dark brown in color. Listed toxic manifestations of drug therapy are an indication of saturation of the body with estrogen and the signal to be reduced to the function of the body, but no antitumor effect on tumor cells. May develop in the majority of cases of primary resistance of tumors, secondary resistance, in which the estrogen cease to be effective. In other words, the patient remains without specific antitumor therapy, and the negative side effects of astroventure accumulate and intensify.

In addition, the known method is carried out for a long time, 1.5-2 months, which also affects the condition of the patient and promotes the development process.

There is a method of treatment of malignant tumors of the genitals, female genitals and breast cancer, is injected into the lymphatic vessels of the rear of the feet or hands of BCG vaccine and methotrexate (Method of immunotherapy of cancer of the female reproductive organs and breast cancer. Auth. mon. NO. 1253009, A 61 K 39/00, AND 61 IN 10/00, 1986).

The described method of treatment allows to achieve significant positive results in terms of the achievement of the mobility of the tumor, reducing its size. In the future, the authors of the method for the obtained effect and prevent possible complications resorted to combined radiation effects on the hearth parstradat its use in the treatment of common forms of prostate cancer. The introduction of the anticancer drug in the lymphatic vessels of the extremities significantly lengthens the path of the drug to the tumor itself, is absorbed on the way, resulting in the tumor affects only a small part of it, decreases the concentration of the drug.

The aim of the invention is to increase the effectiveness of treatment, preventing and reducing existing metastases in bone structures and lymph nodes, reducing the toxic side effects of anticancer chemotherapy.

This goal is achieved by the fact that patients with prostate cancer during surgery enucleation of the testicular parenchyma, after performing the main stage of the operation mobilize the left or right seminal cord, under his shell injected at a depth of about 2 cm of the catheter, fix it methodoloy thread to the shell of the spermatic cord, and then injected into the catheter 400 mg of cyclophosphamide. Similar manipulations performed on the opposite side. Surgical wound is sutured in layers, catheters additionally fixed to the skin. On the seventh day after the operation in each catheter impose additional 400 mg of cyclophosphamide, after which the catheters are removed.

The declarative method has significant alismatidae introduction of anticancer drugs in the immediate vicinity of tumor localization. This allows you to achieve the greatest impact of specific funds for the tumor cells of the tumor itself, existing metastases, prevent new ones.

The Method of treatment of prostate cancer" industrially applicable, it can be reproduced and repeated many times in specialized institutions or urologic surgery.

The method is as follows. After conducting the necessary clinical and laboratory investigations, verification or diagnosis required General preparation of the patient is performed enucleation of the testicular parenchyma. Upon completion of the main phase of the operation highlighted in the right and left seminal cord. Under the shell of the spermatic cord to a depth of 1.5-2 cm catheter, is fixed to the shell of the spermatic cord. In the catheter intraoperatively administered 400 mg of cyclophosphamide, similar manipulations performed on the opposite side. After the introduction of chemotherapy surgical wound is sutured in layers, derived out catheters additionally fixed to the skin. On the 7th day after surgery, the catheter further added 400 mg of cyclophosphamide in each, after which the catheters are removed.

An example of a specific implementation. estopel in the urology Department of the Rostov research Institute 07.05.2000, the survey diagnosed with prostate cancer T3BNM1 CL gr.2, metastases in the bones of the pelvis. Complaints of pain during urination in the crotch, and frequent urination.

DOG blood from 11.04.00 - 80,44 mg/ml

By ultrasound from 21.04.00 - prostate volume 53 cm3- 5,44,15.6 cm, rounded, several asimmetrica at the expense of the left lobe. The contours of the uneven structure is non-uniform areas are not differentiated. In tadakamalla Department, more to the left, hypoechoic focus displacement of 5.5 cm3at the base of the gland between the proximal urethra and becomemore moves the node heterogeneous structure with a volume of 9.5 cm3. Histological study No. 2966-2978 from 24.04.00 - poorly-differentiated adenocarcinoma with diffuse growth of tumor cells in the stroma, germinating in the seminal vesicle.

When finger rectal examination: ampulla of the rectum is free. Prostate 56 cm, rocky density, the mucosa of the rectum above the prostate sedentary.

According to osteointegration from 03.05.00 is defined foci is etnichnyh vertebrae (Fig.1). During movement and at rest, pain in the lumbar region.

19.05.00 performed enucleation of the testicular parenchyma, after performing the main stage of the operation mobilized seed left cord under the shell it introduced approximately at a depth of 2 cm of the catheter is fixed methodoloy thread to the shell of the spermatic cord. The catheter is introduced 400 mg of cyclophosphamide.

Similar manipulations performed on the right side. Operating the wound is sutured in layers, catheters additionally fixed to the skin.

During surgery, the catheter is introduced only 800 mg of cyclophosphamide.

23.05.00 on autologous blood of the patient undergo a course of chemotherapy. Introduced the platinum - 1000 mg of adriamycin - 70 mg, platydema - 150 mg.

26.05.00 in the right and left catheter introduced 400 mg of cyclophosphamide in each. The patient received in the catheter only 1600 mg of cyclophosphamide. Catheters removed.

The patient underwent treatment satisfactorily. Adverse reactions and complications were not observed. PSA from 03.11.00 - 0,00 mg/ml

03.11.00 re digital examination. Ampulla of the rectum is free. Prostate 44 cm, soft elastic consistency, smooth, painless, median furrow smooth. The mucosa of the rectum above the prostate movable.

According to osteosynthesis discharged 17.02.01 in satisfactory condition.

10.10.01 at the next examination the patient is in satisfactory condition. Difficulty with urination does not feel movement in full, in the lumbar region pain are absent.

To date the patient is receiving regular check-UPS.

Technical and economic efficiency of the method lies in the possibility of:

- to introduce into the body of the patient increased number of anticancer drug with a simultaneous reduction of toxic manifestations of the latter;

to achieve recovery of the integrity of the bone structures, the disappearance of metastases;

- to achieve social rehabilitation of patients to improve their quality of life.

Claims

A method of treating prostate cancer, including surgery enucleation of the testicular parenchyma and regional chemotherapy, characterized in that after enucleation of the parenchyma of the testis secrete seminal cord, under whose shell to a depth of 1.5-2 cm catheter and methodoloy thread is fixed to the sheath of the cord, the catheter is administered 400 mg of cyclophosphamide, and similar activities performed on the opposite side, the surgical wound is sutured in layers, catheters additionally fixed to the skin; on the seventh day the Sabbath.

 

Same patents:

The invention relates to a LHRH antagonists - compounds of General formula Iin which a represents acetyl or 3-(4-forfinal)propionyloxy group Xxx1mean D-Nal(1) or D-Nal(2), Xxx2-Xxx3mean D-Cpa-D-Pal(3) or a simple link, Xxx4means Ser, Xxx5means N-Me-Tyr, Xxx6mean D-Hci or a residue of D-amino acids of General formula (II)

where n means the number 3 or 4, a R1means a group of the General formula IIIwhere R denotes an integer from 1 to 4, R2means hydrogen or alkyl group, and R3means unsubstituted or substituted aryl group or heteroaryl group, or R1mean 3-amino-1,2,4-triazole-5-carbonyl group,Xxx7means Leu or Nle, Xxx8means Arg or Lys(iPr), Xxx9means Pro and Xxx10means A1A or Sar, and their salts with pharmaceutically acceptable acids: process for the preparation of these compounds, pharmaceutical compositions having the properties of an LHRH antagonist, comprising as an active narushenie compounds according to the invention has a high solubility in water
The invention relates to the field of pharmaceutical industry and relates to a composition for the prevention and treatment of fibrocystic mastopathy

The invention relates to compounds, which are Aza-derivatives, such as Aza-indiani, Aza-tinalley or Aza-valley, to pharmaceutical compositions and to a method of treatment of pathological conditions such as cancer, bacterial and viral infection

The invention relates to new compounds to metabolites ecteinascidin, namely ETM-305, ETM-204 and ETM-775, having the following structural formula:

These compounds are strong antitumor agents

The invention relates to the production of endostatin mouse and man

The invention relates to compositions containing alcamovia compounds with long-chain unbranched chain, which have the 2-amino and 3-hydroxy-group (except 2-amino-3-hydroxy-C18-alkane) and exhibiting antitumor activity, the way of obtaining

The invention relates to medicine, namely to surgery

The invention relates to medicine, namely to surgery, and may be applicable for indirect access into the cavity of the duodenum
The invention relates to medicine, surgery

The invention relates to medicine, surgery
The invention relates to gynecology

The invention relates to medicine, in particular to surgery, and can be used for the treatment of toxic hepatitis and cirrhosis
The invention relates to medicine, in particular to andrology, and can be used for the treatment of secretory forms of male infertility

The invention relates to medical equipment, namely to medical-surgical instrumentation and surgery, and can be used when Troubleshooting bifurcation stenosis of the coronary arteries in the hospital's cardiology and cardiac surgery departments in providing highly professional operational assistance in emergency conditions

The invention relates to medicine, in particular to surgery, and can be used for the treatment of purulent wounds

The invention relates to medicine, namely to General surgery, in particular to methods of drainage of the gastrointestinal tract
Up!